Pulmonary hypertension: evaluation and management.
Pulmonary hypertension (PH) is a hemodynamic state characterized by elevation in the mean pulmonary arterial pressure and pulmonary vascular resistance leading to right ventricular failure and premature death. PH can be the result of a variety of diseases of different etiologies. Pulmonary arterial hypertension (PAH) should be distinctly differentiated from pulmonary venous hypertension (PVH) as a result of left heart disease. PAH is commonly caused by or associated with an underlying pulmonary, cardiac, or systemic disease (APAH). In the absence of an identifiable etiology or associated underlying disease, PAH is referred to as idiopathic (IPAH). IPAH, formerly known as primary pulmonary hypertension (PPH), is a rare disease most commonly seen in women of childbearing age. Presenting symptoms and signs are nonspecific and include dyspnea on exertion, fatigue, and a loud pulmonary component of the second heart sound. Transthoracic Doppler echocardiography is an excellent noninvasive test to detect the presence of pulmonary hypertension, although every patient should receive a right heart catheterization to confirm the diagnosis. A detailed work up, including laboratory tests and imaging studies, is also indicated to rule out known causes of pulmonary hypertension. Several targeted treatment options have become available in recent years and include parenteral and inhaled prostanoids, oral endothelin receptor antagonists, and oral phosphodiesterase type-5 inhibitors. As a result of their complex care, patients should be referred to centers with expertise in pulmonary hypertension.
Heresi
Gustavo A
GA
Department of Pulmonary, Allergy and Critical Care Medicine, Cleveland Clinic, 9500 Euclid Avenue/A90, Cleveland, OH, 44195, USA.
Dweik
Raed A
RA
D003937:Diagnosis, Differential; D016232:Endothelins / Q000008:administration & dosage / Q000627:therapeutic use; D014943:Global Health; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D007388:Internal Medicine; D009316:National Institutes of Health (U.S.); D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D011320:Primary Health Care; D011453:Prostaglandins / Q000008:administration & dosage / Q000627:therapeutic use; D012042:Registries; D014481:United States
D016232:Endothelins; D010726:Phosphodiesterase Inhibitors; D011453:Prostaglandins